Reshape Lifesciences (STU:24O0) Long-Term Capital Lease Obligation : €0.12 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Long-Term Capital Lease Obligation?

Reshape Lifesciences's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.12 Mil.

Reshape Lifesciences's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.16 Mil) to Dec. 2023 (€0.14 Mil) and declined from Dec. 2023 (€0.14 Mil) to Mar. 2024 (€0.12 Mil).

Reshape Lifesciences's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.14 Mil).

Reshape Lifesciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Reshape Lifesciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Long-Term Capital Lease Obligation Chart

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.43

0.13

0.14

Reshape Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.18	0.16	0.14	0.12

Reshape Lifesciences (STU:24O0) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Reshape Lifesciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (STU:24O0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

RSLS:USA

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines